Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
weissella cibaria sgw054
- Development stage
- Preclinical
- Lead developer
- Metacen Therapeutics
- Modality
- Synthetic Biology Platforms → Engineered Microbial Therapeutics → Microbiome Therapeutics, Fresh FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Yeast Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Bacterial Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Defined Consortia → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Frozen FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Genetically Modified Bacteria → Engineered Microbial Therapeutics → Microbiome Therapeutics, Microbial Metabolites → Microbiome-Derived Products → Microbiome Therapeutics, Microbial Proteins → Microbiome-Derived Products → Microbiome Therapeutics, Complex Communities → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics
- Administration
- Oral
01
Overview
Weissella cibaria SGW054 is a probiotic bacterial strain being investigated for its potential therapeutic effects in Parkinson's disease (PD). It functions as a live biotherapeutic that restores gut microbiota balance and brain homeostasis. In preclinical models, SGW054 has demonstrated antibacterial activity against Proteus mirabilis, a pathogen associated with PD pathology, and has been shown to reduce the translocation of alpha-synuclein aggregates from the gut to the brain. The strain mitigates neuroinflammation by suppressing glial hyperactivation and lowering the release of proinflammatory cytokines, such as tumor necrosis factor-alpha (TNF-alpha), in both the colon and the brain. Additionally, it helps maintain gut barrier integrity and alleviates microbiota dysbiosis by increasing the abundance of beneficial bacteria like Bacteroides and Faecalibacterium.
- Other names
- W. cibaria SGW054
02
Targets
SNCA (Alpha-synuclein)TNFA (Tumor necrosis factor alpha (soluble))
Beyond the preview
Go deeper on weissella cibaria sgw054.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on weissella cibaria sgw054.